Investigating the causal associations between metabolic biomarkers and the risk of kidney cancer

Commun Biol. 2024 Apr 1;7(1):398. doi: 10.1038/s42003-024-06114-8.

Abstract

Metabolic reprogramming plays an important role in kidney cancer. We aim to investigate the causal effect of 249 metabolic biomarkers on kidney cancer from population-based data. This study extracts data from previous genome wide association studies with large sample size. The primary endpoint is random-effect inverse variance weighted (IVW). After completing 249 times of two-sample Mendelian randomization analysis, those significant metabolites are included for further sensitivity analysis. According to a strict Bonferrion-corrected level (P < 2e-04), we only find two metabolites that are causally associated with renal cancer. They are lactate (OR:3.25, 95% CI: 1.84-5.76, P = 5.08e-05) and phospholipids to total lipids ratio in large LDL (low density lipoprotein) (OR: 0.63, 95% CI: 0.50-0.80, P = 1.39e-04). The results are stable through all the sensitivity analysis. The results emphasize the central role of lactate in kidney tumorigenesis and provide novel insights into possible mechanism how phospholipids could affect kidney tumorigenesis.

MeSH terms

  • Biomarkers
  • Carcinogenesis
  • Carcinoma, Renal Cell* / genetics
  • Genome-Wide Association Study
  • Humans
  • Kidney Neoplasms* / genetics
  • Lactic Acid
  • Mendelian Randomization Analysis
  • Phospholipids

Substances

  • Lactic Acid
  • Phospholipids
  • Biomarkers